Want to see SE:MCOV.B full AI Analyst Report?
Top Page
Medicover AB
(MCOV.B)
Select Model
Select Model
Rating:64Neutral
Price Target:
kr258.00
▲(6.17% Upside)
Action:Reiterated
Date:07/23/26
The score is driven primarily by improving operating performance and cash generation, reinforced by a positive earnings update with reaffirmed targets and leverage improving below 3x. These strengths are tempered by balance-sheet leverage risk and a rich valuation (high P/E with a modest dividend), while technicals are supportive but not strongly bullish.
Positive Factors
Organic growth and margins
Double-digit organic growth across both divisions, combined with sequential margin expansion, indicates improving demand and operating execution. If sustained, this growth can strengthen scale economics, support reinvestment, and improve Medicover’s earnings capacity over the next several quarters.
Negative Factors
Elevated leverage
Although leverage has improved recently, debt remains elevated relative to equity and leaves less flexibility than a lightly leveraged healthcare operator. A downturn, higher financing costs, or weaker cash conversion could restrict investment capacity and make balance-sheet repair a persistent priority.
Read all positive and negative factors
Positive Factors
Negative Factors
Organic growth and margins
Double-digit organic growth across both divisions, combined with sequential margin expansion, indicates improving demand and operating execution. If sustained, this growth can strengthen scale economics, support reinvestment, and improve Medicover’s earnings capacity over the next several quarters.
Read all positive factors
Medicover AB (MCOV.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr36.70B
Dividend Yield0.91%
Average Volume (3M)74.38K
Price to Earnings (P/E)38.8
Beta (1Y)0.62
Revenue Growth5.73%
EPS Growth90.34%
CountrySE
Employees49,000
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.56
Shares Outstanding75,424,480
10 Day Avg. Volume43,627
30 Day Avg. Volume74,383
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)5.74
Price to Sales (P/S)1.29
P/FCF Ratio16.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.66
Revenue Forecast (FY)kr2.59B
Medicover AB Business Overview & Revenue Model
Company Description
Established in 1995 and headquartered in Stockholm, Sweden, Medicover AB (publ) is a prominent international provider of both healthcare and diagnostic services. The company operates across numerous countries, including Germany, Sweden, Poland, Tu...
How the Company Makes Money
Medicover makes money primarily by delivering healthcare services and diagnostic tests through its two operating segments. (1) Healthcare Services: revenue is generated from patient care provided in Medicover-owned clinics, medical centers, and ho...
Medicover AB Earnings Call Summary
Earnings Call Date:Jul 22, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 04, 2026
Earnings Call Sentiment Positive
The call presents a broadly positive performance: double-digit organic revenue growth, continued margin expansion across multiple quarters, strong cash generation, reduced leverage under 3x, Diagnostics and India showing robust top-line momentum, and management reaffirming mid-term targets. Key challenges include start-up losses from new Indian hospitals (EUR 3.2m this quarter), some healthcare margin dilution from tough comparables, membership declines in Romania, and political/reimbursement uncertainties in certain markets. Overall, positive operational and financial trends outweigh the manageable headwinds.Positive Updates
Strong Top-Line Growth
Group revenue of EUR 640.4 million, organic revenue growth of 11.8% year-on-year, noting a strong comparable base; Healthcare revenue EUR 442.8 million (up 6.9%, organic 12.2%) and Diagnostics revenue EUR 205.1 million (up 8.5%, organic 10.9%).
Negative Updates
India Start-up Losses and Dilutive Margin
Loss from immature Indian hospitals was EUR 3.2 million in the quarter (majority driven by a very large new hospital), and India remains dilutive to group margins while hospital ramp-up continues.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Top-Line Growth
Group revenue of EUR 640.4 million, organic revenue growth of 11.8% year-on-year, noting a strong comparable base; Healthcare revenue EUR 442.8 million (up 6.9%, organic 12.2%) and Diagnostics revenue EUR 205.1 million (up 8.5%, organic 10.9%).
Read all positive updates
Company Guidance
Management reiterated its mid‑term 2028 targets and commitment to deliver them, specifically organic revenue of €3.25bn and adjusted organic EBITDA of €600m with leverage under 3x, and confirmed they still expect to achieve these milestones; near‑term financial guidance included full‑year CapEx around 6% of revenues (Q2 CapEx €29.7m, 4.6% of revenues; Q2 split ~2/3 Healthcare, 1/3 Diagnostics; maintenance/growth 44/56 this quarter, reverting to ~2/3 growth:1/3 maintenance for the year), a tax‑rate guide of ~26–30% (Q2 ~28%), strengthened liquidity via an RCF increase to €400m (from €300m), and continued focus on margin and cash generation after reporting Q2 revenue €640.4m (organic +11.8%), adjusted EBITDA €109.2m (margin 17.1%), EBIT €51.2m (8% margin, +100bps YoY), EBITDAaL €72.7m (11.3%, +50bps YoY), operating cash flow €73.6m, free cash flow 4.1% of revenues, ROIC 13.6% and leverage at 2.9x (down from 3.1x at year‑end, 3.6x a year ago); dividend of €0.20/share (~€30m) was paid in Q2.Medicover AB Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
52
Neutral
Cash Flow
64
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.47B | 2.38B | 2.09B | 1.75B | 1.51B | 1.38B |
| Gross Profit | 578.37M | 550.70M | 448.30M | 359.40M | 335.60M | 395.00M |
| EBITDA | 396.11M | 377.70M | 171.20M | 257.40M | 215.90M | 274.90M |
| Net Income | 85.12M | 77.50M | 16.70M | 17.60M | 11.80M | 101.80M |
Balance Sheet | ||||||
| Total Assets | 2.44B | 2.42B | 2.14B | 1.94B | 1.83B | 1.68B |
| Cash, Cash Equivalents and Short-Term Investments | 92.70M | 88.20M | 82.80M | 64.40M | 49.10M | 277.90M |
| Total Debt | 1.46B | 1.44B | 1.24B | 1.00B | 940.00M | 764.60M |
| Total Liabilities | 1.88B | 1.88B | 1.65B | 1.41B | 1.32B | 1.12B |
| Stockholders Equity | 536.80M | 532.80M | 464.80M | 496.50M | 474.70M | 517.60M |
Cash Flow | ||||||
| Free Cash Flow | 175.39M | 185.60M | 139.60M | 94.50M | 29.60M | 114.50M |
| Operating Cash Flow | 335.58M | 343.70M | 261.90M | 205.00M | 170.20M | 216.70M |
| Investing Cash Flow | -163.50M | -322.10M | -134.70M | -119.80M | -184.80M | -333.60M |
| Financing Cash Flow | -157.40M | -5.80M | -108.00M | -73.70M | -24.30M | 164.10M |
Medicover AB Technical Analysis
Positive
243.00
Price Trends
232.29
Positive
219.66
Positive
214.13
Positive
Market Momentum
4.01
Positive
56.62
Neutral
47.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MCOV.B, the sentiment is Positive. The current price of 243 is above the 20-day moving average (MA) of 238.90, above the 50-day MA of 232.29, and above the 200-day MA of 214.13, indicating a bullish trend. The MACD of 4.01 indicates Positive momentum. The RSI at 56.62 is Neutral, neither overbought nor oversold. The STOCH value of 47.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:MCOV.B.
Medicover AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | kr690.86M | 18.56 | ― | ― | 8.98% | -16.41% | |
71 Outperform | kr3.35B | 19.77 | 5.55% | 1.93% | -3.48% | -14.02% | |
68 Neutral | kr12.97B | 17.96 | 15.11% | 1.55% | 13.33% | 28.61% | |
65 Neutral | kr18.31B | 18.24 | ― | 0.74% | -1.07% | 81.76% | |
64 Neutral | kr36.70B | 38.79 | ― | 0.91% | 5.73% | 90.34% | |
56 Neutral | kr28.01B | 41.01 | ― | 0.53% | ― | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
SE:MCOV.B
Medicover AB
241.50
-23.73
-8.95%
SE:ATT
Attendo AB
121.50
53.00
77.37%
SE:HUM
Humana AB
69.80
30.32
76.81%
SE:AMBEA
Ambea AB
171.50
43.45
33.93%
SE:CARE
Careium AB
28.40
5.10
21.89%
SE:ASKER
Asker Healthcare Group AB
73.00
-19.67
-21.23%
Medicover AB Corporate Events
Medicover Sells Indian Hospital Unit to KKR to Refocus on Europe
Aug 6, 2026
Medicover AB has agreed to sell 100 per cent of its Medicover Hospitals India business to funds managed by KKR, valuing the Indian unit at EUR 1.2 billion. The divested platform consists of 24 hospitals with about 4,800 beds and 11,400 employees, ...
Medicover lifts revenue, margins and cash flow in Q2 2026
Jul 22, 2026
Medicover AB is a leading international healthcare and diagnostic services group founded in 1995, operating ambulatory clinics, hospitals, specialty-care facilities, laboratories and blood-drawing points. Its largest markets are Poland, Germany, R...
Medicover Sets Date and Format for Q2 2026 Results Presentation
Jul 13, 2026
Medicover AB will publish its Q2 2026 results on 22 July at 07:45 CEST, underscoring its ongoing role as a major listed healthcare and diagnostics group in Europe and key emerging markets. The company plans an English-language conference call and ...
Medicover Confirms Talks With KKR on Potential Sale of Indian Operations
Jun 17, 2026
Medicover AB, a Stockholm-based provider of healthcare and diagnostic services, runs extensive clinic, hospital and laboratory networks across Europe and India. Its largest specialty-care blood-drawing markets include Poland, Germany, Romania and ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.